Greenland Mines Ltd. (NASDAQ: GRML) announced that Innovation, Science and Economic Development Canada has granted a patent covering technology exclusively licensed by the company for Klotho-based gene therapies targeting cognition, memory and neurodegenerative diseases. The patent protects the use of the secreted Klotho (“s-KL”) RNA splice variant in genetic therapies and includes 42 claims covering its synthesis, delivery methods and potential application across multiple neurological disorders, including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis.
The company said the Canadian patent expands its intellectual property portfolio for Klotho-based therapeutics and complements previously issued patents in the United States, China and Europe. This milestone strengthens Greenland Mines’ position in the biotech sector, particularly for its lead candidates KLTO-101 and KLTO-202. The company added that process development and manufacturing for KLTO-101 is scheduled to begin in August 2026, while KLTO-202 has advanced to GMP manufacturing as the company prepares for regulatory interactions later this year.
Greenland Mines operates two divisions: mining and biotech. The mining division focuses on the Skaergaard Project in southeast Greenland and the Sarfartoq neodymium-praseodymium rare earths project in southwest Greenland. The biotech division includes Klotho’s KLTO-202 primary indication for ALS. The company’s strategy is centered on building a multi-asset platform with exposure to rare earth magnet materials, precious metals and selected midstream processing opportunities, while advancing its broader North Atlantic Critical Metals Corridor vision linking Greenland resources with allied downstream jurisdictions and industrial infrastructure.
For more details, the full press release is available at https://ibn.fm/x2pHA. The latest news and updates relating to GRML are available in the company’s newsroom at https://ibn.fm/GRML.
